Table E4.
Relationship between the occurrence of delayed events (in the 72 hours after LAIV) and baseline characteristics
| Factor | Level | All delayed AEs | P value | Lower respiratory tract AEs only | P value |
|---|---|---|---|---|---|
| Age | Median, IQR | 8.7 (5.0-12.3) | .02 | 7.8 (4.2-11.9) | .01 |
| Age 2-4 y | 35 of 77 (45%) | 18 of 77 (23%) | |||
| Age 5-11 y | 65 of 220 (30%) | 24 of 220 (11%) | |||
| Age 12+ y | 39 of 143 (27%) | 14 of 143 (10%) | |||
| Baseline (c)ACT or TRACK score | Q1∗ | 34 of 92 (37%) | .12† | 12 of 92 (13%) | .77† |
| Q2∗ | 33 of 97 (34%) | 15 of 97 (15%) | |||
| Q3∗ | 44 of 145 (30%) | 17 of 145 (12%) | |||
| Q4∗ | 28 of 103 (27%) | 12 of 103 (12%) | |||
| Lung function (FEV1 or PEFR) | >95% | 30 of 106 (28%) | .59† | 12 of 106 (11%) | .97† |
| 95%-90% | 12 of 38 (32%) | 4 of 38 (11%) | |||
| 89%-90% | 14 of 55 (25%) | 3 of 55 (5%) | |||
| 79%-70% | 9 of 36 (25%) | 6 of 36 (17%) | |||
| 69%-60% | 7 of 20 (35%) | 1 of 20 (5%) | |||
| 59%-50% | 4 of 10 (40%) | 2 of 10 (20%) | |||
| <50% | 1 of 2 (50%) | 0 of 2 (0%) | |||
| Baseline ACQ score | 0-4 | 41 of 160 (26%) | .22† | 14 of 160 (9%) | .23† |
| 5-9 | 28 of 94 (30%) | 10 of 94 (11%) | |||
| 10-14 | 20 of 58 (34%) | 11 of 58 (19%) | |||
| 15-19 | 6 of 30 (20%) | 1 of 30 (3%) | |||
| 20-24 | 8 of 17 (47%) | 2 of 17 (12%) | |||
| 25-30 | 1 of 3 (33%) | 0 of 3 (0%) | |||
| “Persistent poor control” | No | 70 of 235 (30%) | .41 | 26 of 235 (11%) | .31 |
| Yes | 69 of 205 (34%) | 30 of 205 (15%) | |||
| High-dose ICS | No | 73 of 257 (28%) | .10 | 28 of 257 (11%) | .19 |
| Yes | 66 of 183 (36%) | 28 of 183 (15%) | |||
| “Difficult asthma” | No | 97 of 316 (31%) | .57 | 35 of 316 (11%) | .11 |
| Yes | 42 of 124 (34%) | 21 of 124 (17%) | |||
| Atopic status | |||||
| Eczema | No | 64 of 224 (29%) | .18 | 31 of 224 (14%) | .57 |
| Yes | 75 of 216 (35%) | 25 of 216 (12%) | |||
| Allergic rhinitis | No | 46 of 168 (27%) | .14 | 21 of 168 (13%) | 1.0 |
| Yes | 93 of 272 (34%) | 35 of 272 (13%) | |||
| IgE-mediated food allergy | No | 79 of 239 (33%) | .54 | 34 of 239 (14%) | .32 |
| Yes | 60 of 201 (30%) | 22 of 201 (11%) | |||
| Previous influenza vaccine | No | 42 of 119 (35%) | .42 | 13 of 119 (11%) | .63 |
| Yes | 96 of 308 (31%) | 41 of 308 (13%) |
PEFR, Peak expiratory flow rate.
Four children met the criteria for severe exacerbation within 72 hours, aged 3, 4, 7, and 15 years; 3 had coexisting atopy, and 2 (aged 3 and 7 years) had previously received LAIV.
∗
Data analyzed in quartiles, for ACT this was <15,15-18,19-22, and ≥23; for TRACK, <35, 35-50, 55-65, and ≥70.
†
Trend test across categories.